Explore

Trendline Trendline
Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus

Cingulate Inc. Advances ADHD Treatment Amid Regulatory Focus
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio

Neurocrine Biosciences Acquires Soleno Therapeutics in $2.9 Billion Deal, Expanding Rare Disease Portfolio
Trendline Trendline
Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights
Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders
Trendline Trendline
Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth

Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth

Amphastar Pharmaceuticals to Present at Needham Healthcare Conference Highlighting Strategic Growth
Trendline Trendline
Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges

Gilead Sciences Extends Tender Offer for Arcellx Amid Biotech M Challenges
Trendline Trendline
Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Claims Following Trial Discontinuation
Trendline Trendline
Takeda Ends Partnership with Denali, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali, Returns Dementia Drug Rights
Trendline Trendline
API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'

API's Strategic Approach to Drug Development Aims to Overcome 'Valley of Death'
Trendline Trendline
Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions

Sanofi's Lunsekimig Shows Mixed Results in Phase 2 Trials for Respiratory and Skin Conditions
Trendline Trendline
Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial

Sanofi's Lunsekimig Shows Promise in Asthma and Rhinosinusitis, Falls Short in Eczema Trial
Trendline Trendline
Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Class Action

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Class Action

Rosen Law Firm Investigates Immutep Ltd. for Potential Securities Class Action